Special Offer: Get 50% off your first 2 months when you do one of the following
Personalized offer codes will be given in each session

Developing Vaccine Therapies Addressing Notable Unmet Needs in Lung Cancer

About This Webinar

OSE Immunotherapeutics Key Opinion Leader Webinar

The event will feature Dr Stephen Liu, medical oncologist, Georgetown University (Washington DC, United States), who will discuss the unmet medical need and therapeutic landscape in lung cancer.

Professor Benjamin Besse, medical oncologist, director of clinical research at the Gustave Roussy Institute (Villejuif, France), will present the Artemia study, the registration Phase III clinical trial of Tedopi® in non-small cell lung cancer.

Soo Romanoff, managing director of healthcare at Edison Group, will chair the panel and Q&A.

About OSE Immunotherapeutics

OSE Immunotherapeutics (PAR: OSE) is a leading biotech company committed to pioneering breakthroughs in immune-oncology and immuno-inflammation. At the forefront of its portfolio is Tedopi®, a revolutionary cancer vaccine that has recently demonstrated promising outcomes in a Phase III study involving non-small cell lung cancer patients facing secondary resistance following checkpoint inhibitor treatment. The company’s R&D pipeline is robust and diverse, ensuring that its progress remains resilient and independent of any singular subsector.

Who can view: Everyone
Webinar Price: Free
Featured Presenters
Webinar hosting presenter
Medical Oncologist, Georgetown University
Dr. Stephen V. Liu is an Associate Professor at Georgetown University's Lombardi Comprehensive Cancer Center. With extensive training from Johns Hopkins University and the University of Southern California, he focuses on innovative treatments for lung cancer and related malignancies. He leads the Thoracic Oncology section and the Phase I Developmental Therapeutics group. His work has been published in journals such as the New England Journal of Medicine, Journal of Clinical Oncology, Journal of Thoracic Oncology, Lancet Oncology, Cancer Discovery and Clinical Cancer Research.
Webinar hosting presenter
Medical Oncologist, Director of Clinical Research at Gustave Roussy Institute (IGR, Villejuif, France)
Professor Benjamin Besse is a renowned medical oncologist specializing in thoracic cancer, currently serving as Director of the Research Clinique Gustave Roussy. With expertise in personalized treatment approaches and early drug development, he has authored over 250 peer-reviewed articles and led numerous clinical trials. Besse holds leadership roles in prominent scientific councils and networks, including Chair of the EORTC Scientific Chairs Council and coordinator of RYTHMIC, the French network for malignant thymic tumors.
Webinar hosting presenter
Chief Executive Officer of OSE Immunotherapeutics
Nicolas Poirier holds a PhD in Immunology (European Center for Transplantation and Immunotherapy Sciences, Nantes), a double master’s degree in Biotechnology from the University of Nantes and in Pharmacology from the University of Louis Pasteur in Strasbourg and a certification in Global Management from INSEAD.
Over the past fifteen years, he has authored more than 50 peer-reviewed international scientific publications and holds over 40 issued patents in the field of immunotherapy. Nicolas Poirier and his team have obtained more than 45 million euros in French and European public funding to co-finance OSE Immunotherapeutics’ research and development programs.